350 related articles for article (PubMed ID: 27344172)
1. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
Rocha CR; Kajitani GS; Quinet A; Fortunato RS; Menck CF
Oncotarget; 2016 Jul; 7(30):48081-48092. PubMed ID: 27344172
[TBL] [Abstract][Full Text] [Related]
2. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
3. Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo.
Rocha CR; Garcia CC; Vieira DB; Quinet A; de Andrade-Lima LC; Munford V; Belizário JE; Menck CF
Cell Death Dis; 2014 Oct; 5(10):e1505. PubMed ID: 25356874
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line.
Zhou Y; Wang HD; Zhu L; Cong ZX; Li N; Ji XJ; Pan H; Wang JW; Li WC
Oncol Rep; 2013 Jan; 29(1):394-400. PubMed ID: 23128449
[TBL] [Abstract][Full Text] [Related]
6. p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma cells against TMZ.
Ma L; Liu J; Zhang X; Qi J; Yu W; Gu Y
Med Oncol; 2015 Mar; 32(3):69. PubMed ID: 25691294
[TBL] [Abstract][Full Text] [Related]
7. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy.
Lin CJ; Lee CC; Shih YL; Lin TY; Wang SH; Lin YF; Shih CM
Free Radic Biol Med; 2012 Jan; 52(2):377-91. PubMed ID: 22094224
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
9. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
10. Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis.
Zhu Z; Du S; Du Y; Ren J; Ying G; Yan Z
J Neurochem; 2018 Jan; 144(1):93-104. PubMed ID: 29105080
[TBL] [Abstract][Full Text] [Related]
11. TMZ-induced PrPc/par-4 interaction promotes the survival of human glioma cells.
Zhuang D; Liu Y; Mao Y; Gao L; Zhang H; Luan S; Huang F; Li Q
Int J Cancer; 2012 Jan; 130(2):309-18. PubMed ID: 21328340
[TBL] [Abstract][Full Text] [Related]
12. CD147 confers temozolomide resistance of glioma cells via the regulation of β-TrCP/Nrf2 pathway.
Bu X; Qu X; Guo K; Meng X; Yang X; Huang Q; Dou W; Feng L; Wei X; Gao J; Sun W; Chao M; Han L; Hu Y; Shen L; Zhang J; Wang L
Int J Biol Sci; 2021; 17(12):3013-3023. PubMed ID: 34421346
[No Abstract] [Full Text] [Related]
13. IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
Li K; Ouyang L; He M; Luo M; Cai W; Tu Y; Pi R; Liu A
Oncotarget; 2017 Apr; 8(17):28865-28879. PubMed ID: 28427200
[TBL] [Abstract][Full Text] [Related]
14. KLF8 Promotes Temozolomide Resistance in Glioma Cells via β-Catenin Activation.
Yu G; Wu F; Wang E
Cell Physiol Biochem; 2016; 38(4):1596-604. PubMed ID: 27081861
[TBL] [Abstract][Full Text] [Related]
15. Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.
Gong A; Ge N; Yao W; Lu L; Liang H
Cancer Chemother Pharmacol; 2014 Sep; 74(3):531-8. PubMed ID: 25047724
[TBL] [Abstract][Full Text] [Related]
16. Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death.
Cheng Y; Sk UH; Zhang Y; Ren X; Zhang L; Huber-Keener KJ; Sun YW; Liao J; Amin S; Sharma AK; Yang JM
PLoS One; 2012; 7(4):e35104. PubMed ID: 22496897
[TBL] [Abstract][Full Text] [Related]
17. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Kim SM; Woo JS; Jeong CH; Ryu CH; Jang JD; Jeun SS
Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
[TBL] [Abstract][Full Text] [Related]
18. The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.
Hayashi T; Adachi K; Ohba S; Hirose Y
J Neurooncol; 2013 Nov; 115(2):169-78. PubMed ID: 23943501
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.
Liu XY; Zhang L; Wu J; Zhou L; Ren YJ; Yang WQ; Ming ZJ; Chen B; Wang J; Zhang Y; Yang JM
PLoS One; 2013; 8(11):e81345. PubMed ID: 24303044
[TBL] [Abstract][Full Text] [Related]
20. A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo.
Chen TC; Cho HY; Wang W; Nguyen J; Jhaveri N; Rosenstein-Sisson R; Hofman FM; Schönthal AH
Cancer Lett; 2015 Mar; 358(2):144-151. PubMed ID: 25524552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
